AR024472A1 - Inhibidores de la integrina alfav beta6. - Google Patents
Inhibidores de la integrina alfav beta6.Info
- Publication number
- AR024472A1 AR024472A1 ARP000103177A ARP000103177A AR024472A1 AR 024472 A1 AR024472 A1 AR 024472A1 AR P000103177 A ARP000103177 A AR P000103177A AR P000103177 A ARP000103177 A AR P000103177A AR 024472 A1 AR024472 A1 AR 024472A1
- Authority
- AR
- Argentina
- Prior art keywords
- ala
- asp
- arg
- phe
- gly
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/02—Linear peptides containing at least one abnormal peptide link
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Biophysics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Péptidos de la formula 1, que son biologicamente activos como ligandos de la integrina alfav beta6 Ac-Arg-X1-Asp-X2-X3-X4-X5-X6-NH2 (1) donde Ac significaacetilo, X1 significa Ser, Gly, Thr, Asp, Arg, Val, Tyr, His o Ala, X2 significa Leu, Ile, Nle,Val o Phe, X3 significa Asp, Glu, Lys, Phe, Aib, Nal, Gly, Ala,Bgl o Phg, X4 significa Gly, Ala, Ser, beta-Ala o omega-Abu, X5 significa Leu, Ile, Nle, Val o Phe, X6 significa Arg, Har, Lys, Orn, Phe, Ala, Tyr, Gly, Ser oAsp donde los aminoácidosmen cionados también pueden ser derivatizados los radicales de los aminoácidos están unidos entre sí en forma de péptido por medio delos grupos alfa-amino y alfa-carboxi, están incluidos tanto las formas D como las L de los radicales aminoácidoopticamen te activos, así como sus sales, ydonde queda excluido Ac-Arg-Thr-Asp-Leu-Asp-Ser-Leu-Arg-NH2. Los péptidos de acuerdo con la invencion se pueden aplicar como inhibidores efectivos del receptoralfav beta6 y, por lo tanto, se pueden emplearpara el tra tamiento de diversas enfermedades y estados patologicos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19929410A DE19929410A1 (de) | 1999-06-26 | 1999-06-26 | Inhibitoren des Integrins avß6 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR024472A1 true AR024472A1 (es) | 2002-10-02 |
Family
ID=7912712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP000103177A AR024472A1 (es) | 1999-06-26 | 2000-06-23 | Inhibidores de la integrina alfav beta6. |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1189930A1 (es) |
| JP (1) | JP2003503422A (es) |
| KR (1) | KR20020015704A (es) |
| CN (1) | CN1358195A (es) |
| AR (1) | AR024472A1 (es) |
| AU (1) | AU771099B2 (es) |
| BR (1) | BR0011954A (es) |
| CA (1) | CA2377224A1 (es) |
| CZ (1) | CZ20014484A3 (es) |
| DE (1) | DE19929410A1 (es) |
| HU (1) | HUP0201729A3 (es) |
| MX (1) | MXPA01013247A (es) |
| NO (1) | NO20016341L (es) |
| PL (1) | PL352374A1 (es) |
| SK (1) | SK18722001A3 (es) |
| WO (1) | WO2001000660A1 (es) |
| ZA (1) | ZA200200673B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6972296B2 (en) | 1999-05-07 | 2005-12-06 | Encysive Pharmaceuticals Inc. | Carboxylic acid derivatives that inhibit the binding of integrins to their receptors |
| AU2004208865B2 (en) * | 2003-02-06 | 2010-06-17 | Merck Patent Gmbh | Peptidic sulfonamides |
| GB0520068D0 (en) | 2005-10-03 | 2005-11-09 | Cancer Res Technology | av peptide ligand |
| CA2658612C (en) | 2006-08-03 | 2015-11-17 | Astrazeneca Ab | Antibodies directed to .alpha.v.beta.6 and uses thereof |
| KR102634762B1 (ko) * | 2016-11-01 | 2024-02-06 | 애로우헤드 파마슈티컬스 인코포레이티드 | 알파-v 베타-6 인테그린 리간드 및 그의 용도 |
| CR20200178A (es) | 2017-11-01 | 2020-06-28 | Arrowhead Pharmaceuticals Inc | Ligandos de integrina y usos de estos |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2029392A (en) * | 1991-05-14 | 1992-12-30 | Board Of Regents Of The University Of Oklahoma, The | Peptide inhibitors of inflammation |
| ATE410179T1 (de) * | 1997-08-08 | 2008-10-15 | Univ California | Behandlung von leberfibrose mit anti-alpha v beta 6 integrin antikörpern |
| WO2000037487A1 (de) * | 1998-12-19 | 2000-06-29 | Merck Patent Gmbh | INHIBITOREN DES INTEGRINS αvβ¿6? |
-
1999
- 1999-06-26 DE DE19929410A patent/DE19929410A1/de not_active Withdrawn
-
2000
- 2000-06-13 HU HU0201729A patent/HUP0201729A3/hu unknown
- 2000-06-13 CZ CZ20014484A patent/CZ20014484A3/cs unknown
- 2000-06-13 AU AU62630/00A patent/AU771099B2/en not_active Ceased
- 2000-06-13 WO PCT/EP2000/005404 patent/WO2001000660A1/de not_active Application Discontinuation
- 2000-06-13 SK SK1872-2001A patent/SK18722001A3/sk unknown
- 2000-06-13 CA CA002377224A patent/CA2377224A1/en not_active Abandoned
- 2000-06-13 MX MXPA01013247A patent/MXPA01013247A/es unknown
- 2000-06-13 EP EP00949177A patent/EP1189930A1/de not_active Withdrawn
- 2000-06-13 KR KR1020017016580A patent/KR20020015704A/ko not_active Application Discontinuation
- 2000-06-13 CN CN00809493A patent/CN1358195A/zh active Pending
- 2000-06-13 JP JP2001507066A patent/JP2003503422A/ja active Pending
- 2000-06-13 BR BR0011954-7A patent/BR0011954A/pt not_active IP Right Cessation
- 2000-06-13 PL PL00352374A patent/PL352374A1/xx unknown
- 2000-06-23 AR ARP000103177A patent/AR024472A1/es not_active Application Discontinuation
-
2001
- 2001-12-21 NO NO20016341A patent/NO20016341L/no not_active Application Discontinuation
-
2002
- 2002-01-24 ZA ZA200200673A patent/ZA200200673B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| HUP0201729A3 (en) | 2005-01-28 |
| MXPA01013247A (es) | 2002-07-02 |
| CA2377224A1 (en) | 2001-01-04 |
| SK18722001A3 (sk) | 2002-05-09 |
| HUP0201729A2 (en) | 2002-08-28 |
| JP2003503422A (ja) | 2003-01-28 |
| AU771099B2 (en) | 2004-03-11 |
| NO20016341D0 (no) | 2001-12-21 |
| KR20020015704A (ko) | 2002-02-28 |
| BR0011954A (pt) | 2002-05-07 |
| EP1189930A1 (de) | 2002-03-27 |
| CN1358195A (zh) | 2002-07-10 |
| CZ20014484A3 (cs) | 2002-04-17 |
| PL352374A1 (en) | 2003-08-25 |
| DE19929410A1 (de) | 2000-12-28 |
| ZA200200673B (en) | 2003-04-24 |
| NO20016341L (no) | 2002-02-25 |
| WO2001000660A1 (de) | 2001-01-04 |
| AU6263000A (en) | 2001-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR039231A1 (es) | Agentes de union ox40r novedosos | |
| NL300013I1 (nl) | Nieuwe protein met TNF-remmende werking en hun ber | |
| CY1105616T1 (el) | ΠΕΠΤΙΔΙΑ ΑΝΑΣΤΟΛΕΙΣ ΤΟΥ TGFβ1 | |
| ES2160485B1 (es) | Peptidos inhibidores de la exocitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen. | |
| DK1941867T3 (da) | Polypeptid med modificeret Kunitz domæne | |
| CY1110927T1 (el) | Αμινο-καταληκτικως διακλαδισμενη rantεs ως ανταγωνιστης των χημοκινων | |
| DE60331546D1 (de) | Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung | |
| ATE171712T1 (de) | Neuartiger menschlicher proteaseinhibitor vom kunitz-typ und entsprechende varianten | |
| DE69009476D1 (de) | Hemmung des reaktionswegs für die n-ende-regel in lebenden zellen. | |
| AR024472A1 (es) | Inhibidores de la integrina alfav beta6. | |
| MXPA02000465A (es) | Derivados ciclopeptidicos como inhibidores de la integrina alfav beta6. | |
| ATE443076T1 (de) | Von protease typ ii spaltbares peptid | |
| US20080171697A1 (en) | Peptides Having For Example Antiangiogenic Activity and Applications Thereof In Therapeutics | |
| ES2058873T3 (es) | Antagonistas peptidicos sinteticos de neuroquinina a, sus sales y procedimientos de preparacion respectivos. | |
| AR020101A1 (es) | Un antagonista peptido del receptor de uroquinasa humana, composicion farmaceutica que lo contiene, su uso para la manufactura de un medicamento y metodopara seleccionar un antagonista peptido adecuado. | |
| NO20034146L (no) | Syntetiske peptider og fremgangsmåte for forebyggende og terapeutisk anvendelse i kreftinvasjon og metastase | |
| DE60120507D1 (de) | Menschliches leucinereiche wiederholungen enthaltendes protein, vorwiegend im dünndarm exprimiert, hlrrsi1 | |
| TH57872B (th) | สารยับยั้งของอินทีกริน อัลฟานู เบตา6 | |
| ATE456576T1 (de) | Splice variante des menschlichen hypophysären wachstumshormons | |
| ATE438660T1 (de) | Neue menschliche g-protein gekoppelten rezeptoren und dafür kodierende polynucleotide | |
| TH56074A3 (th) | ตัวยับยั้ง อัลฟาv เบตา6 อินทีกริน | |
| ES2119746T3 (es) | Nuevo peptido fisiologicamente activo y agente regulador del metabolismo del calcio que comprende dicho peptido como ingrediente activo. | |
| TH56074B (th) | ตัวยับยั้ง (อัลฟาv เบตา6) อินทีกริน | |
| LT2004079A (en) | Sythetic peptides and uses therof for the prevention and therapy of cancer invasion and metastasis | |
| Yusuf et al. | 1-Tetralinyl as Carboxamide-Protecting Group for Asparagine and Application to N-α-t-Butyloxycarbonyl (Boc) Solid-phase Peptide Synthesis of Oxytocin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |